ERBB2 and breast carcinoma: The Western blot analysis of the protein expression showed a significantly higher expression of RBMS3 in the control cell line than in the MCF-7 and BT-474 cancer cell lines (ANOVA and Bonferroni’s multiple comparison test p < 0.05, Figure 4b) There is a visible and statistically significant trend that the more aggressive types of breast cancer, including TNBC and HER-2-positive cancers, presented higher expression of RBMS3 than their benign counterparts.